Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konstantin Christov

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Current Cancer Drug Targets|March 12, 2009
The novel RARbeta isoform (beta5) is a potential target of retinoids in breast cancerKonstantin Christov
Anticancer Research|August 23, 2003
Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequencySteven M Swanson, Konstantin Christov
International Journal of Oncology|May 23, 2015
Retinoids induce cellular senescence in breast cancer cells by RAR-β dependent and independent pathways: Potential clinical implications (Review)Anne Shilkaitis, Albert Green, Konstantin Christov
International Journal of Oncology|September 18, 2004
Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoidsXinjian Peng, Duri Yun, Konstantin Christov
Oncology Reports|June 6, 2007
Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestinRonald D Wiehle, Konstantin Christov, Rajendra Mehta
Cancer Prevention Research (Philadelphia, Pa.)|December 2, 2010
CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosisRonald Wiehle, Daniel Lantvit, Tohru Yamada, et al.
Neoplasia (New York, N.Y.)|May 3, 2011
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesisDipankar Ray, Yasuhisa Terao, Konstantin Christov, et al.
Cancer Letters|May 3, 2005
Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor beta2 expressionXinjian Peng, Steven Wood, Laura Bratescu, et al.
Oncogene|November 24, 2004
Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cellsXinjian Peng, Rajendra G Mehta, Debra A Tonetti, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 23, 2013
Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesisAnne Shilkaitis, Laura Bratescu, Albert Green, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Current Cancer Drug Targets|March 12, 2009
The novel RARbeta isoform (beta5) is a potential target of retinoids in breast cancerKonstantin Christov
Anticancer Research|August 23, 2003
Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequencySteven M Swanson, Konstantin Christov
International Journal of Oncology|May 23, 2015
Retinoids induce cellular senescence in breast cancer cells by RAR-β dependent and independent pathways: Potential clinical implications (Review)Anne Shilkaitis, Albert Green, Konstantin Christov
International Journal of Oncology|September 18, 2004
Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoidsXinjian Peng, Duri Yun, Konstantin Christov
Oncology Reports|June 6, 2007
Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestinRonald D Wiehle, Konstantin Christov, Rajendra Mehta
Cancer Prevention Research (Philadelphia, Pa.)|December 2, 2010
CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosisRonald Wiehle, Daniel Lantvit, Tohru Yamada, et al.
Neoplasia (New York, N.Y.)|May 3, 2011
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesisDipankar Ray, Yasuhisa Terao, Konstantin Christov, et al.
Cancer Letters|May 3, 2005
Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor beta2 expressionXinjian Peng, Steven Wood, Laura Bratescu, et al.
Oncogene|November 24, 2004
Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cellsXinjian Peng, Rajendra G Mehta, Debra A Tonetti, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 23, 2013
Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesisAnne Shilkaitis, Laura Bratescu, Albert Green, et al.
Pageof 5